Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
A new study conducted by Baylor College of Medicine and presented at the American College of Cardiology Annual Scientific Session as well as the World Congress of Cardiology shows that an oral PCSK9 inhibitor called MK-0616...
Read Full NewsThe rheumatology year in review highlights FDA approvals and pivotal data readouts.
Johnson & Johnson plans to initiate a phase 3 study based off the positive data.
Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.
Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.
The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.
Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101
Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression
1.
NEJM: Fluorescent guide can aid in the detection of tumors that are still present after breast cancer surgery.
2.
In a randomized trial, the kinder, gentler regimen for classical Hodgkin wins out.
3.
FDA Expands Durvalumab Label to Operable Lung Cancer
4.
New guidelines expand access to lung cancer screening, but gaps remain in reaching rural and uninsured populations
5.
There is a 40% reduction in the risk of 9 cancers with good cardiorespiratory fitness.
1.
The Architect's Dilemma: Remodeling the Tumor Microenvironment for a New Era of Cancer Immunotherapy
2.
Harnessing Artificial Intelligence in Oncology: Innovations in Diagnosis, Treatment, and Patient Care
3.
Unveiling the Hidden Benefits of Lymphedema Treatment
4.
IGF2BP1 in Blood Disorders: Therapeutic Potential and Comprehensive Functional Insights
5.
Florinef: Understanding Its Uses and Side Effects
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
3.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
4.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge